AMLX
Amylyx Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Russell 3000
$28.86Close
$3.2BMarket cap
$11.38 – $39.6652-week range
Nov 5, 2026Next report
Highlights
Strengths
- Leading the market RS 97 · stronger than 97% of stocks over 12 months
Cautions
- Trend not confirmed 6 of 8 conditions · under the 50-day, over 25% off the high
- Far from its high 27% below its 52-week high
- Distribution down-day volume 2.2× up-day volume over 50 sessions
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
27%
1wk
up 6.1%
price change
1mo
down 0.8%
price change
12-month return
up 105%
market up 11% ·
its own up 97%
F-score
—
— Not assessed
Altman Z
65.88
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
10.4×
price / book
Earnings yield
down 5.2%
EBIT / enterprise value
Cheaper than
13%
of the market · expensive
Revenue growth
down 100%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 62%
return on equity
Free cash margin
—
-$123.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.8%
$1.37 a day · 2×ATR $26.12
RS
97 / 99
vs the universe
Trend
6 / 8
under the 50-day, over 25% off the high
Relative volume
0.6×
vs 50-day average
Up/down volume
0.46
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 6 of 8
- Price above the 50-day average: fails
- Within 25% of the 52-week high: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 60.1% over the year, from 69m to 110m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 100.0% over the year.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+4% vs market2 sessions after results
Financials
- Gross
- Net
- Free cash
- Cash
- Long-term debt
| FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|
| Revenue | $285,000 | $22.2M | $380.8M | $87.4M | $0 |
| Gross margin | — | 87% | 93% | 93% | — |
| Operating income | -$82.7M | -$201.3M | $38.8M | -$314.7M | -$153.3M |
| Net income | -$87.9M | -$198.4M | $49.3M | -$301.7M | -$144.7M |
| Net margin | -30853% | -892% | 13% | -345% | — |
| Earnings per share | -$13.35 | -$3.39 | $0.70 | -$4.43 | -$1.53 |
| Free cash flow | -$75.2M | -$182.4M | $10.7M | -$167.8M | -$123.5M |
| Free cash margin | -26369% | -820% | 3% | -192% | — |
| Cash | $50.2M | $62.5M | $170.2M | $77.4M | $226.7M |
| Shareholders' equity | -$151.2M | $340.6M | $433.4M | $164.8M | $305.3M |
| Shares outstanding | 7.02m | 66.51m | 67.71m | 68.63m | 109.88m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 4, 2025 | Annual ↗ | Dec 31, 2024 | 63d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 8, 2026 | Material agreement ↗ |
| Aug 20, 2026 | Material agreement ↗ |
| Aug 18, 2026 | Other events ↗ |
| Aug 18, 2026 | Regulation FD · Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 4, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Mar 24, 2026 | Regulation FD ↗ |
| Mar 3, 2026 | Results ↗ |
| Jan 8, 2026 | Regulation FD · Other events ↗ |
| Nov 6, 2025 | Results ↗ |
| Sep 10, 2025 | Material agreement ↗ |